Casdin discloses 9.7% BioLife Solutions stake (NASDAQ: BLFS)
Casdin Capital and its affiliates have disclosed a 9.7% beneficial ownership stake in BioLife Solutions (NASDAQ: BLFS), totaling 4,757,165 common shares. The stake was acquired for investment purposes using the fund's working capital, without specific borrowing. While currently having no concrete plans for corporate changes, Casdin reserves the right to engage with management and other shareholders to maximize shareholder value and may adjust its holdings in the future.
[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity
A recent Form 4 filing indicates significant insider selling activity for BioLife Solutions Inc. (BLFS) by Casdin Partners Master Fund, L.P. The fund sold a total of 1.2 million shares of common stock across three transactions from May 19 to May 21, 2026, at prices ranging from $22.65 to $23.70. Despite these sales, Casdin Partners Master Fund still retains a substantial indirect holding of 4,757,165 shares in BLFS.
Casdin Partners (NASDAQ: BLFS) files Form 144 for 650,000-share resale notice
Casdin Partners Master Fund, L.P. has filed a Form 144 notice with the SEC, indicating their intent to sell 650,000 shares of Biolife Solutions Inc. (NASDAQ: BLFS) common stock. The filing also details past dispositions of 300,000 shares on May 19, 2026, and 250,000 shares on May 20, 2026, handled by BMO Capital Markets. This notice is for transparency and does not change BLFS's outstanding share count.
Summit Creek Advisors LLC Grows Stock Holdings in BioLife Solutions, Inc. $BLFS
Summit Creek Advisors LLC increased its stake in BioLife Solutions (NASDAQ:BLFS) by 24.2% in Q4 2025, bringing its total to 238,802 shares valued at $5.77 million. This comes despite significant insider selling, with Karen A. Foster selling nearly $1.95 million worth of shares. BioLife Solutions reported stronger-than-expected earnings for its latest quarter, though analyst ratings for the medical equipment provider remain mixed, with a consensus "Hold."
Why BioLife Solutions (BLFS) Is Up 13.4% After Q1 Return To Profitability And Reaffirmed Outlook
BioLife Solutions (BLFS) saw its stock rise by 13.4% following a profitable Q1 2026, where sales reached US$27.5 million and net income hit US$1.19 million, a return from a previous loss. The company reaffirmed its 2026 revenue outlook of US$112.5 million to US$115.0 million and expects full-year GAAP net income, reinforcing confidence in the demand for its cell and gene therapy support products despite ongoing risks related to customer concentration. BioLife's investment narrative projects significant revenue and earnings growth by 2028, with a fair value estimate suggesting a 35% upside.
BLFS (NASDAQ) affiliate notifies sale of 250,000 shares via BMO Capital Markets
An affiliate of BioLife Solutions (BLFS) has filed a Form 144 to notify the proposed sale of 250,000 shares of common stock through BMO Capital Markets. The filing indicates these shares were originally purchased from the issuer on August 13, 2018, and also discloses a prior sale of 300,000 shares on May 19, 2026, which generated gross proceeds of $6,795,000. This is a routine disclosure required for affiliate sales, not an execution report, and does not confirm the completion or timing of the proposed sale.
BioLife (NASDAQ: BLFS) proposed sale of 300,000 shares, $6.69M listed
BioLife Solutions (NASDAQ: BLFS) has filed a Form 144 indicating a proposed sale of 300,000 shares of common stock, valued at $6.69 million. These shares were originally purchased directly from the issuer on August 13, 2018, and BMO Capital Markets is listed as the broker-dealer for the planned resale. The filing notes 48,857,415 shares outstanding as of May 19, 2026.
Number of shareholders of BioLife Solutions, Inc. – NASDAQ:BLFS
This article from TradingView provides information on the number of shareholders for BioLife Solutions, Inc. (NASDAQ: BLFS). It appears to be a financial data page rather than a news article, focusing on presenting stock-related metrics for the company. The content includes general market and stock information without detailed shareholder numbers.
T. Rowe Price (BLFS) reports 6.51M shares, 13.5% stake disclosed
T. Rowe Price Investment Management, Inc. has disclosed a beneficial ownership of 6,506,346 shares in Biolife Solutions Inc. (BLFS), representing a 13.5% stake. This information comes from a Schedule 13G/A amendment filed on May 15, 2026, which states T. Rowe Price has sole voting and dispositive power over these shares. A portion of this stake, specifically 2,562,102 shares (5.3%), is held by the T. Rowe Price Small-Cap Stock Fund.
BioLife Solutions, Inc. (NASDAQ:BLFS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
BioLife Solutions, Inc. (NASDAQ:BLFS) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $32.00. The company recently beat earnings estimates, reporting $0.02 EPS against an expected $0.01 and $27.5 million in revenue against $25.66 million. Despite insider selling, institutional investors hold a significant 93.24% of the company's stock, indicating strong institutional confidence.
BioLife Solutions (NASDAQ:BLFS) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS
BioLife Solutions (NASDAQ:BLFS) reported strong Q1 results, beating EPS estimates by $0.03 with $0.04 EPS and exceeding revenue forecasts with $27.5 million. The company's revenue grew 25% year-over-year, driven by biopreservation media, and it reaffirmed its full-year 2026 guidance, expecting GAAP net income. Despite temporary gross margin pressure from bag yield issues, BioLife Solutions is expanding its product portfolio and maintains a "Moderate Buy" consensus rating from analysts.
BioLife Solutions (BLFS) Q4 Profit Challenges Ongoing Loss Narrative
BioLife Solutions (BLFS) recorded a profitable Q4 2025 with US$24.8 million in revenue and US$0.04 basic EPS, contrasting with a full-year loss. While analysts forecast significant revenue and earnings growth by 2028, the company currently trades at a premium P/S multiple despite ongoing trailing losses. Investors are keenly watching if the Q4 profitability marks a turning point to validate its high valuation and growth expectations.
BioLife Solutions Q1 2026 Earnings Call Transcript
BioLife Solutions reported a solid start to 2026 with Q1 revenue up 25% year-over-year to $27.5 million, driven primarily by biopreservation media (BPM). The company reaffirmed its 2026 revenue guidance of $112.5M-$115M and expects to achieve full-year GAAP net income for the first time in many years. Despite bag yield issues temporarily impacting gross margins, the company is addressing this, with recovery expected by Q4 2026 or Q1 2027, and continues to expand its product portfolio beyond BPM.
BioLife Solutions reports Q1 2026 revenue $27.5M, adjusted EBITDA $6.2M, GAAP net income $1.2M
BioLife Solutions announced its first-quarter 2026 results, reporting $27.5 million in revenue, a 25% year-over-year increase, and a GAAP net income of $1.2 million. The company also achieved a 64% gross margin (GAAP and adjusted) and a non-GAAP adjusted EBITDA of $6.2 million. Management reiterated its full-year 2026 revenue guidance of $112.5M–$115.0M.
Earnings call transcript: BioLife Solutions Q1 2026: Revenue Surges, Stock Rises
BioLife Solutions (BLFS) reported strong Q1 2026 earnings, with revenue reaching $27.5 million, exceeding forecasts by 7.09%, and EPS matching expectations at $0.02. The company saw a 25% year-over-year revenue increase, primarily from its Biopreservation Media (BPM) franchise, leading to a 6.39% rise in stock price during aftermarket trading. Despite temporary manufacturing challenges impacting gross margins, BioLife Solutions maintains a positive full-year outlook, projecting 17-20% revenue growth and anticipating full-year GAAP net income for the first time in many years.
Earnings Flash (BLFS) BioLife Solutions, Inc. Reports Q1 Revenue $27.5M, vs. FactSet Est of $25.7M
BioLife Solutions, Inc. (BLFS) announced its Q1 revenue reached $27.5 million, surpassing FactSet's estimate of $25.7 million. The company is a supplier of cell processing tools and services for the cell and gene therapy market, offering products like CryoStor freeze media, HypoThermosol storage media, Sexton cell processing products, CellSeal cryogenic vials, CryoCase containers, and ThawSTAR automated thawing devices. BioLife Solutions reported 155 employees and is covered by 10 analysts, with a mean consensus rating of "BUY".
BioLife Solutions (NASDAQ: BLFS) grows Q1 2026 revenue 25%
BioLife Solutions reported first-quarter 2026 revenue of $27.5 million, marking a 25% increase year-over-year, alongside a GAAP net income of $1.2 million and adjusted EBITDA of $6.2 million. The company reaffirmed its 2026 revenue guidance of $112.5–$115.0 million, expecting 17–20% growth. BioLife Solutions continues to hold a significant market share in biopreservation media for cell and gene therapy clinical trials.
BioLife Solutions earnings up next as profitability test looms
BioLife Solutions is set to report its first-quarter results, with investors keenly watching to see if the biopreservation specialist can maintain its recent profitability after surprising Wall Street last quarter. Analysts anticipate earnings of $0.02 per share on $25.68 million in revenue. The company's strategic pivot towards higher-margin consumables and its partnership with Qkine Limited are key areas of focus, as BioLife aims for consistent GAAP net income in a rapidly expanding cell and gene therapy market.
Invesco reports 2.35M BioLife shares (NASDAQ: BLFS) holding 4.9%
Invesco Ltd. has filed an amended Schedule 13G/A, disclosing beneficial ownership of 2,348,532 shares of BioLife Solutions Inc. (NASDAQ: BLFS), which represents a 4.9% stake in the company. The filing, signed by Invesco's Global Head of Compliance, indicates that Invesco holds sole voting power over 2,113,765 shares and sole dispositive power over all 2,348,532 shares, asserting a passive investment intent. This report provides key metrics on Invesco's ownership, including voting and dispositive powers, and clarifies that the stake is below the 5% threshold typically signaling a more controlling interest.
Executive pay, bonuses and board structure at BioLife Solutions (NASDAQ: BLFS)
BioLife Solutions, Inc. filed an amended annual report (10-K/A) for 2025 detailing executive compensation and corporate governance, as it does not plan to file a proxy statement. The company reported strong revenue growth in 2025, reaching $96.2 million, and outlined its compensation philosophy, which links executive bonuses and equity awards to company performance metrics such as revenue and adjusted EBITDA margin. CEO Roderick de Greef's total compensation for 2025 was approximately $10.47 million, reflecting the company's financial achievements and strategic transitions during the year.
BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
BioLife Solutions, Inc. announced it will release its first quarter 2026 financial results on May 7, 2026. The company will host a conference call and live webcast to discuss these results and provide a general business update at 4:30 PM ET on the same day. BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy market.
BioLife Solutions schedules May 7 earnings call, webcast at 4:30 ET
BioLife Solutions (NASDAQ: BLFS) announced that it will release its Q1 2026 financial results on May 7, 2026. The company will host a conference call and live webcast at 4:30 PM ET on the same day to discuss the results and provide a business update. A replay of the webcast will be available for 90 days on the investor relations website.
BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) announced it will release its first-quarter 2026 financial results on May 7, 2026. This will be followed by a conference call and live webcast at 4:30 PM ET (1:30 PM PT) where management will discuss the financial results and provide a business update. The webcast will be available on the BioLife Solutions investor relations page, and a replay will be archived for 90 days.
Discover BioLife Solutions And 2 Other Stocks That May Be Priced Below Their Estimated Value
The U.S. market has seen significant growth, rising 1.7% in the last 7 days and 34% over the past year, with earnings projected to increase by 16% annually. This article highlights three companies—BioLife Solutions (BLFS), Prosperity Bancshares (PB), and Vishay Precision Group (VPG)—that are currently trading below their estimated fair values based on future cash flows, presenting potential investment opportunities. Each company's overview includes its market cap, revenue segments, estimated discount to fair value, recent financial performance, and growth forecasts.
BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
BioLife Solutions has won the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system designed for frozen biologic materials. The CryoCase addresses issues with flexible cryobags by offering reinforced structural protection and allowing for visual inspection of container integrity. This award validates the product's importance for cell and gene therapy manufacturing as it scales towards commercialization.
BioLife’s CryoCase wins award for tackling frozen therapy bag failures
BioLife Solutions (NASDAQ: BLFS) has won the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system designed to prevent failures common with flexible cryobags in cell and gene therapy manufacturing. Launched in 2025, CryoCase provides reinforced structural protection during freezing, liquid nitrogen storage, and distribution, addressing a significant industry need for improved containment and visual inspection of frozen biologic materials. This award validates the product's importance as CGT programs move towards commercialization and regulatory scrutiny increases.
Utah Medical Gains 32% in a Year: Should You Buy the Stock?
Utah Medical Products (UTMD) has seen its shares rise 31.5% over the past year, outperforming the industry, due to its strong niche positioning, global diversification, and robust financial health. While the company benefits from favorable long-term healthcare trends and clinician-driven innovation, it faces challenges from regulatory burdens, competitive pressures, and a valuation higher than the industry average. Long-term investors might find UTMD's fundamentals appealing, but new investors might consider waiting for a more favorable entry point.
BioLife Solutions (BLFS) EVP has 515 shares withheld for taxes
BioLife Solutions EVP and Chief Scientific Officer Mathew Aby J. had 515 shares of common stock withheld by the company to cover tax obligations at $19.27 per share, due to the release of restricted stock units. This was not an open-market trade. After this transaction, he directly holds 390,167 shares of BioLife Solutions common stock.
[Form 4] BIOLIFE SOLUTIONS INC Insider Trading Activity
Todd Berard, Chief Marketing Officer of BIOLIFE SOLUTIONS INC (BLFS), reported a routine insider transaction where 293 shares of common stock were withheld for tax obligations related to the release of restricted stock units. This was not an open-market sale, and after the transaction, Berard directly holds 163,768 shares. The filing indicates a neutral impact and sentiment on the company.
BioLife (NASDAQ: BLFS) CFO RSU vesting triggers tax withholding
BioLife Solutions Inc. CFO Troy Wichterman had 844 shares of common stock withheld on April 8, 2026, to cover tax obligations arising from the vesting of restricted stock units. The shares were valued at $19.27 each, and Wichterman now holds 216,056 shares directly. This transaction was a tax-withholding disposition, not an open-market sale, and is a common method for handling taxes on equity compensation.
Wall Street Analysts Think BioLife Solutions (BLFS) Could Surge 70.78%: Read This Before Placing a Bet
Wall Street analysts project a potential 70.78% upside for BioLife Solutions (BLFS), with an average price target of $32.67. While price targets alone might be misleading, the company also boasts a Zacks Rank #1 (Strong Buy) due to strong earnings estimate revisions, suggesting potential for near-term stock price movement. Investors are advised to use price targets as a starting point for further research, coupled with critical skepticism.
BLFS Stock Price, Quote & Chart | BIOLIFE SOLUTIONS INC (NASDAQ:BLFS)
This article provides detailed stock information for BioLife Solutions Inc. (NASDAQ: BLFS), including its current stock price, performance metrics, key statistics, technical and fundamental analysis ratings from ChartMill, and insights into its latest earnings report and analyst forecasts. The company specializes in biopreservation tools for cells and tissues.
378,550 Shares in BioLife Solutions, Inc. $BLFS Purchased by Capricorn Fund Managers Ltd
Capricorn Fund Managers Ltd recently acquired a significant stake of 378,550 shares in BioLife Solutions (NASDAQ:BLFS), valued at approximately $9.15 million, making BLFS its 12th largest position. Despite insider sales totaling over $2 million in the last three months, institutional investors own 93.24% of the stock. Analysts currently hold a "Moderate Buy" consensus rating with a target price of $32.00 for BioLife Solutions, which specializes in biopreservation and cold chain solutions for advanced biologics.
BLFS Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of BioLife Solutions Inc (BLFS), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company primarily generates revenue from Product Revenue-Cell processing, showing strong gross margins but a negative Return on Equity. It also benchmarks BLFS's financial performance against industry leaders like STAA and CDNA.
BioLife Solutions (BLFS) executive sells 2,577 shares under 10b5-1 plan
Karen A. Foster, Chief Quality and Operations at BioLife Solutions (BLFS), sold 2,577 shares of common stock at a weighted average price of $19.17 per share. This transaction was conducted under a pre-arranged Rule 10b5-1(c) trading plan adopted in December 2025. Following the sale, Foster directly holds 108,758 shares of BioLife Solutions common stock.
Global Biostorage Service Market Size is Expected to Reach USD 655.81 Million by 2026
The global Biostorage Service market is projected to reach $1,658.22 million by 2033, growing from $655.81 million in 2026 with a CAGR of 14.17%. This growth is driven by advancements in precision medicine, biopharmaceutical R&D, and the expansion of new drug development. Key market players include Azenta, Thermo Fisher Scientific, and EPL Archives (VWR), with North America being the largest market.
Foster Karen A., chief quality and operations, sells BioLife Solutions (BLFS) shares for $49k
Karen A. Foster, Chief Quality and Operations at BioLife Solutions Inc (NASDAQ:BLFS), recently sold 2,577 shares for a total of $49,401 under a Rule 10b5-1 trading plan. This insider sale occurred as BLFS trades just 7% above its 52-week low and is down 22% year-to-date. Despite the insider sale, the company reported strong financial performance in Q4 2025, exceeding analysts' expectations for both EPS and revenue.
BioLife Solutions Inc (BLFS) Stock Price Quote Today & Current Price Chart
This entry appears to be a stub or an incomplete article. It mentions BioLife Solutions Inc (BLFS) stock price quotes and current price charts, suggesting it is a financial data page. The only content provided points to "Online Trading with Smart Investment App" from Capital.com.
Vanguard (BLFS) Amendment shows 0 shares and 0% after Jan 12, 2026 realignment
Vanguard Group filed an amended Schedule 13G/A for BioLife Solutions Inc. (BLFS), reporting 0 shares and 0% beneficial ownership an internal realignment on January 12, 2026, which led to disaggregated reporting by its subsidiaries. This change is purely an accounting and disclosure adjustment, not an actual sale of shares by Vanguard, and reflects a switch to separate reporting by its various units based on SEC guidance. The filing clarifies that Vanguard Group no longer has beneficial ownership of BLFS shares held by these subsidiaries but does not indicate any change in aggregate shareholder ownership levels or transaction activity.
BLFS SEC Filings - Biolife Solutions Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Biolife Solutions Inc. (BLFS) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms. It offers detailed information on the company's activities in cell processing tools, bioproduction products, and financial reporting. The platform also provides AI-powered summaries of these filings to help investors understand key points and corporate governance decisions.
BioLife Solutions (BLFS) CMO uses shares to cover tax bill
BioLife Solutions Inc. (BLFS) Chief Marketing Officer Todd Berard reported an insider tax-withholding transaction where 1,879 shares of common stock were withheld to cover his tax obligations upon the release of restricted stock units. This non-market disposition leaves Berard with 164,061 directly held shares of BioLife Solutions common stock. This is a routine transaction for equity compensation tax liabilities.
BioLife Solutions (BLFS) CEO uses 11,101 shares for tax withholding
Roderick De Greef, President and CEO of BioLife Solutions Inc. (BLFS), had 11,101 shares of common stock withheld to cover taxes on vested restricted stock units. This transaction was a tax-withholding disposition, meaning the shares were delivered back to the company rather than sold on the open market. Following this, De Greef directly holds 733,746 shares of BioLife Solutions common stock.
BioLife Solutions (BLFS) CFO has shares withheld to cover RSU taxes
BioLife Solutions Inc.'s CFO, Troy Wichterman, had 3,749 shares of common stock withheld at $19.12 per share to cover tax obligations related to the vesting of restricted stock units (RSUs). This was a routine, non-market transaction to satisfy taxes, not a sale, and Wichterman retains a significant equity position of 216,900 shares after the transaction. This type of insider transaction is generally considered a neutral signal as it's an administrative event for equity compensation.
BioLife Solutions, Inc. (NASDAQ:BLFS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
BioLife Solutions, Inc. (NASDAQ:BLFS) has received a consensus "Moderate Buy" rating from five brokerages, with an average one-year price target of $32.00. Despite a negative P/E ratio indicating unprofitability, the company, which specializes in biopreservation solutions for cell and gene therapies, has seen significant institutional investment and some insider selling. The stock is currently trading at $19.12, below its 1-year high of $29.62.
BioLife Solutions, Inc. $BLFS Shares Sold by Granahan Investment Management LLC
Granahan Investment Management LLC significantly reduced its stake in BioLife Solutions (NASDAQ:BLFS) by 39% in the third quarter, selling 251,104 shares. This transaction leaves them with 392,096 shares, valued at approximately $10 million. Additionally, insiders have been selling shares, with Karen A. Foster disposing of 96,923 shares and a total of 101,956 insider shares sold in the last three months.
BioLife Solutions, Inc. $BLFS Shares Sold by Fred Alger Management LLC
Fred Alger Management LLC reduced its stake in BioLife Solutions (NASDAQ:BLFS) by 11.1% in Q3, selling 139,106 shares and retaining over 1.1 million shares valued at approximately $28.3 million. Company insiders also sold about 101,956 shares worth $2.07 million last quarter, with Karen A. Foster being a significant seller. Analysts currently hold a "Moderate Buy" rating for BLFS with a consensus target price of $32.00, despite the stock trading below its 50- and 200-day moving averages.
BioLife Solutions, Inc. (BLFS) surpasses Q4 earnings and revenue estimates
BioLife Solutions, Inc. (BLFS) announced strong fourth-quarter results, surpassing both earnings and revenue estimates. The company reported adjusted earnings of $0.09 per share, significantly outperforming the Zacks Consensus Estimate of a $0.05 loss, and revenues of $37.2 million, exceeding the estimate of $35.45 million. This positive performance was largely driven by robust growth in its cell processing and storage and distribution segments.
BioLife Solutions, Inc. (BLFS) surpasses Q4 earnings and revenue estimates
BioLife Solutions, Inc. (BLFS) exceeded Q4 earnings and revenue expectations. This performance indicates a stronger financial footing than anticipated by analysts. Further details within the full report would likely elaborate on the factors contributing to this positive outcome.
BioLife Solutions, Inc. $BLFS is Casdin Capital LLC's 2nd Largest Position
Casdin Capital LLC has made BioLife Solutions (BLFS) its second-largest holding, despite reducing its stake by 13% in Q3. The article highlights significant insider selling, with two executives selling shares totaling over $2 million. Wall Street analysts currently rate BLFS as a "Moderate Buy" with an average price target of $32.00, while the stock trades between $18–$25.
BLFS - Biolife Solutions Inc Latest Stock News & Market Updates
This page provides news and analysis for Biolife Solutions (BLFS), a developer of cell processing tools and services for the cell and gene therapy markets. It covers financial results, strategic transactions, product developments, and corporate updates. Recent news includes details on preliminary Q2 2020 revenue, a public stock offering, and second-quarter financial results.
